CytomX Therapeutics (CTMX) provided an update on the CX-2051 Phase 1 study to address certain recent social media posts. CX-2051 Program Status: CX-2051 dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses, administered every three weeks have each enrolled approximately 20 patients as planned. A single Grade 5 treatment-related acute kidney injury occured in a patient with a complex medical history including having a solitary kidney. The Grade 5 event was believed to be secondary to nausea, vomiting and diarrhea. The Company was made aware of the event on July 11, 2025 and promptly reported the event to the FDA on July 18, 2025 in accordance with regulatory requirements. The CTMX-2051-101 Safety Review Committee convened on July 14, 2025 and supported continued study execution and enrollment. The CTMX-2051-101 study is ongoing. A Phase 1 data update is expected by Q1 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics Earnings Call: Clinical Progress and Financial Strength
- Promising Clinical Progress and Efficacy of CytomX Therapeutics’ CX-2051 Justifies Buy Rating
- CytomX Therapeutics Reports Strong Financial Turnaround
- CytomX Therapeutics reports Q2 EPS 0c, consensus (6c)
- CytomX Therapeutics files $250M mixed securities shelf